A Study to Confirm the Efficacy and Safety of Different Dupilumab Dose Regimens in Adults With Atopic Dermatitis (AD)
Completed · Phase 3 · NCT02395133
Conditions: Atopic Dermatitis
At a glance
- Research payments reported, 2025
- $2,668
- U.S. investigators named
- 0
- Sites paid
- 0
- Planned or actual enrollment
- 422
About the trial
- Sponsor
- Regeneron Pharmaceuticals (with Sanofi)
- Tested
- Dupilumab (drug), Placebo (drug)
- Dates
- Started 2015-03-25; completion 2016-10-18
- Results posted
- Yes
The primary objective of the study was to assess the ability of different Dupilumab dose regimens, administered as monotherapy, to maintain the treatment response achieved after 16 weeks of initial treatment with Dupilumab monotherapy compared to placebo.
From ClinicalTrials.gov, last updated 2020-03-11. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Genzyme Corporation reported $2,668 in research payments for this study in 2025 (5 payments).
Products named: Dupixent
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
Sites paid to run it
- $2,668
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.